Steep Barriers to Overcome for Successful Application of Stem Cell Treatment in Patients with Idiopathic Pulmonary Fibrosis

摘要

We read with great interest the review article by Toonkel and colleagues published in the Journal wherein authors summarize the current state of knowledge regarding the therapeutic potential of mesenchymal stem cells (MSCs) and highlight the need for phase I clinical trials to overcome safety concerns. Although we support the authors' recommendation, we would like to highlight a number of steep barriers that apply to implementation of stem cell therapies in idiopathic pulmonary fibrosis (IPF). These barriers need to be addressed cautiously to circumvent potential conflicting and disappointing results as has recently occurred with MSC trials in patients with myocardial infarction and chronic obstructive pulmonary disease (PROCHYMAL study).